PERAN ANTIHISTAMIN DALAM DERMATOLOGI: TINJAUAN FARMAKOLOGI, EFIKASI KLINIS, DAN KEAMANAN PADA KEHAMILAN

Yosserizal Yosserizal; Anggi Syafitri Nasution; Arientina Amanda Filia; Vioni Yolisa Fitri; Muhammad Zaky; Dessy Abdullah

doi:10.59003/nhj.v5i1.1675

Authors

Yosserizal Yosserizal RSUD Achmad Mochtar
Anggi Syafitri Nasution Universitas Baiturrahmah
Arientina Amanda Filia Universitas Baiturrahmah
Vioni Yolisa Fitri Universitas Baiturrahmah
Muhammad Zaky Universitas Baiturrahmah
Dessy Abdullah Universitas Baiturrahmah

DOI:

https://doi.org/10.59003/nhj.v5i1.1675

Keywords:

Antihistamines, Dermatology, Allergy, Pregnancy, Adverse Effects

Abstract

Antihistamines are widely used as first-line therapy for allergic skin disorders such as urticaria, dermatitis, and pruritus. Understanding their pharmacological mechanisms, classification, and safety profiles is essential for effective clinical application, particularly for long-term use and during pregnancy. This article is a narrative review based on scientific literature from national and international databases (PubMed, Scopus, SINTA), focusing on pharmacology, classification, clinical indications, contraindications, adverse effects, and safety of antihistamines in pregnancy. Antihistamines act as inverse agonists at histamine receptors, primarily H1 and H2. First-generation agents are lipophilic, crossing the blood–brain barrier and causing sedation, while second-generation antihistamines act selectively on peripheral receptors with fewer central nervous system side effects. During pregnancy, cetirizine and loratadine are recommended due to favorable safety profiles compared to first-generation drugs. In dermatology, antihistamines are effective in managing urticaria, angioedema, lichen simplex chronicus, mastocytosis, and various allergic skin conditions. The selection of antihistamines should be guided by pharmacokinetics, side effect profile, patient-specific conditions, and pregnancy safety. Second-generation antihistamines are generally preferred for long-term management owing to their efficacy and reduced central nervous system risk.

Downloads

Download data is not yet available.

References

Akdis CA, Simons FE, Histamine and histamine receptors in allergic disease. J Allergy Clin Immunol. 2020;145(5):1209–1223. doi:10.1016/j.jaci.2020.02.012.

Church MK, Maurer M. Antihistamines in urticaria: An overview. Clin Transl Allergy. 2015;5:33. doi:10.1186/s13601-015-0078-0.

Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for urticaria. Allergy. 2022;77(3):734–766. doi:10.1111/all.15090.

Simons FE, Simons KJ. H1 antihistamines: Current status and future directions. World Allergy Organ J. 2011;4(3):57–63. doi:10.1097/WOX.0b013e31821188c3.

Simons FE. Advances in H1-antihistamines. N Engl J Med. 2014;371:740–748. doi:10.1056/NEJMra1306354.

Gupta A, Singh S, Kumar S. Comparative efficacy of H1 and H2 blockers in chronic urticaria. Indian J Dermatol. 2017;62(4):400–406. doi:10.4103/ijd.IJD_280_17.

Hartmann K, Escribano L, Grattan C, Brockow K, Carter MC, Alvarez-Twose I, et al. Cutaneous manifestations in patients with mastocytosis: Consensus report. J Allergy Clin Immunol. 2016;137(1):35–45. doi:10.1016/j.jaci.2015.10.048.

Agostoni C, et al. First-generation H1-antihistamines and cognitive impairment in the elderly. Drugs Aging. 2020;37(6):389–396. doi:10.1007/s40266-020-00765-7.

Woosley RL, Romero K, Heise CW, Gallo T. QT drug lists. CredibleMeds. 2017. Available from: https://www.crediblemeds.org

Farzam K, Sabir S, O’Malley M. Antihistamines. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK538188/

Gilboa SM, Strickland MJ, Olshan AF, et al. Use of antihistamine medications during early pregnancy and isolated major malformations. Birth Defects Res A Clin Mol Teratol. 2014;100(6):480–488. doi:10.1002/bdra.23250.

Matok I, Gorodischer R, Koren G, et al. The safety of loratadine and antihistamines during pregnancy: A prospective controlled cohort study. J Clin Pharmacol. 2013;53(8): 954–960. doi:10.1002/jcph.105.

Etwel F, Faught L, Rieder MJ, Koren G. The risk of adverse pregnancy outcome after first trimester exposure to H1 antihistamines: A systematic review and meta-analysis. Drug Saf. 2017;40(2):121–132. doi:10.1007/s40264-016-0479-9.

Kar S, Krishnan A, Preetha K, Mohankar A. A review of antihistamines used during pregnancy. J Pharmacol Pharmacother. 2012;3(2):123–128. doi:10.4103/0976-500X.95503.

Shawky RM, Seifeldin NS. The relation between antihistamine medication during early pregnancy and birth defects. Egypt J Med Hum Genet. 2015;16(3):243–250. doi:10.1016/j.ejmhg.2015.04.003.

Isman HSM, Iskandar Y. Penggunaan Antihistamin dalam Terapi Kondisi Alergi pada Masa Kehamilan. Farmaka. 2023;16(1):310–321.

Puspita AL, Aulia G, Utami SM, Suryaningsih IA. Evaluasi Penggunaan Antihistamin pada Pasien Dermatitis di Klinik Kulit RS X Tangerang Selatan. Jurnal Farmasi Klinis Indonesia. 2024;1(1):18–24.

Wisesa TW. Penggunaan antihistamin dalam bidang dermatologi. In: Ilmu Penyakit Kulit dan Kelamin, Edisi ke-7. Jakarta: Universitas Sriwijaya Press; 2018. p. 411–416.